Overall, our findings present a robust combination therapy centered on regulating liver inflammation to treat MASLD through co-administration of siNotch1 and AMD3100 simultaneously suppressing the Notch1 signaling pathway and CXCR4. Here, NOTCH1 is linked to metabolic dysfunction-associated steatotic liver disease.